FTO Promotes Hepatocellular Carcinoma Progression by Mediating m6A Modification of BUB1 and Targeting TGF-βR1 to Activate the TGF-β Signaling Pathway
FTO is overexpressed in HCC and is associated with poor clinical outcomes. Mechanistically, FTO promotes HCC progression by stabilizing BUB1 mRNA through an m6A-YTH domain family 2-dependent pathway, which activates TGF-β signaling. Targeting the FTO-BUB1-TGF-βR1 regulatory network may offer a promising therapeutic strategy for HCC.
Authors
- Zhechuan Mei (ORCID: https://orcid.org/0000-0001-9766-3684)
- Lin Zhang
- Li Gan (ORCID: https://orcid.org/0000-0002-1459-2321)
- Shengtao Liao (ORCID: https://orcid.org/0009-0003-3150-7840)
- Yu‐Ru Lin
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Jiangjin Central Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Clinical and Translational Hepatology
- Published
- 2025-04-18
- DOI
- https://doi.org/10.14218/jcth.2025.00007
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Centre Scientifique et Technique du Bâtiment